MabThera SC for subcutaneous formulation
E822403
MabThera SC for subcutaneous formulation is a subcutaneously administered version of the monoclonal antibody rituximab, used primarily in the treatment of certain blood cancers and autoimmune diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| MabThera SC for subcutaneous formulation canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9807104 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: MabThera SC for subcutaneous formulation Context triple: [MabThera, isMarketedAs, MabThera SC for subcutaneous formulation]
-
A.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
B.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
C.
Skyrizi
Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
-
D.
Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: MabThera SC for subcutaneous formulation Target entity description: MabThera SC for subcutaneous formulation is a subcutaneously administered version of the monoclonal antibody rituximab, used primarily in the treatment of certain blood cancers and autoimmune diseases.
-
A.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
B.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
C.
Skyrizi
Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
-
D.
Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
Statements (25)
| Predicate | Object |
|---|---|
| instanceOf |
pharmaceutical drug
ⓘ
rituximab-containing medicinal product ⓘ subcutaneous formulation ⓘ |
| administrationSite | subcutaneous tissue ⓘ |
| belongsToRegimen | rituximab-based chemotherapy regimens ⓘ |
| brandOf | MabThera ⓘ |
| drugClass | monoclonal antibody ⓘ |
| hasActiveIngredient |
rituximab
ⓘ
linked to:
Rituxan
|
| hasDosageForm | solution for injection ⓘ |
| indication |
certain autoimmune disorders
ⓘ
chronic lymphocytic leukemia ⓘ non-Hodgkin lymphoma ⓘ |
| isBiologic | true ⓘ |
| isBrandNameOf | rituximab subcutaneous formulation ⓘ |
| isFormulationOf |
rituximab
ⓘ
linked to:
Rituxan
|
| isParenteral | true ⓘ |
| isSubcutaneousVersionOf | intravenous rituximab ⓘ |
| mechanismOfAction | B-cell depletion ⓘ |
| pharmacologicalClass | anti-CD20 monoclonal antibody ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| target |
CD20 antigen
ⓘ
linked to:
CD20 protein
|
| therapeuticArea |
immunology
ⓘ
oncology ⓘ |
| usedFor |
treatment of certain autoimmune diseases
ⓘ
treatment of certain blood cancers ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: MabThera SC for subcutaneous formulation Description of subject: MabThera SC for subcutaneous formulation is a subcutaneously administered version of the monoclonal antibody rituximab, used primarily in the treatment of certain blood cancers and autoimmune diseases.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.